FY2027 Earnings Forecast for TLX Issued By William Blair

Telix Pharmaceuticals Limited American Depositary Shares (NASDAQ:TLX) – Stock analysts at William Blair decreased their FY2027 EPS estimates for shares of Telix Pharmaceuticals Limited American Depositary Shares in a research report issued to clients and investors on Wednesday, March 12th. William Blair analyst A. Hsieh now expects that the company will post earnings per share of $1.44 for the year, down from their previous forecast of $1.46. William Blair has a “Outperform” rating on the stock. The consensus estimate for Telix Pharmaceuticals Limited American Depositary Shares’ current full-year earnings is $0.24 per share.

Separately, UBS Group raised their price target on shares of Telix Pharmaceuticals Limited American Depositary Shares from $21.00 to $22.00 and gave the company a “buy” rating in a report on Monday, January 27th.

Telix Pharmaceuticals Limited American Depositary Shares Stock Down 1.0 %

Shares of NASDAQ:TLX opened at $16.99 on Thursday. The firm has a fifty day moving average price of $17.42. Telix Pharmaceuticals Limited American Depositary Shares has a one year low of $14.01 and a one year high of $30.36.

Telix Pharmaceuticals Limited American Depositary Shares Company Profile

Telix Pharmaceuticals Ltd. engages in the development and commercialization of several clinical-stage oncology assets. It operates through the following segments: Commercial, Product Development, and Group and Unallocated. The Commercial segment includes sales of Illuccix and other products subsequent to obtaining regulatory approvals.